FUNDACIO INSTITUT GUTTMANN

Their core work

Institut Guttmann is a specialist neurorehabilitation center based near Barcelona, focused on the clinical management and recovery of patients with spinal cord injury, acquired brain injury, and stroke. Their H2020 work reflects two complementary capabilities: contributing patient cohorts and clinical expertise to experimental therapy trials (such as Nogo-A antibody treatment in acute spinal cord injury), and providing clinical data and domain knowledge to large-scale predictive modeling projects for stroke outcomes. As a foundation-run research and care institution, they sit at the intersection of hospital practice and applied neuroscience research — giving them direct access to patient populations that purely academic partners cannot offer. Their value in consortia is grounded in real clinical settings, not laboratory models.

What they specialise in

How they've shifted over time

In their first H2020 project (starting 2016), Institut Guttmann's focus was firmly in experimental clinical neuroscience — specifically the biological mechanisms of spinal cord repair, including neural plasticity, axonal regeneration, and the pharmacological use of Nogo-A inhibitors in tetraplegia. By 2018, their second project shifted to a data-driven paradigm: stroke, personalised medicine, machine learning, and large-scale data harmonisation replaced the bench-to-bedside biology focus. This suggests a deliberate broadening from a single highly specialised condition (SCI) toward a more methodology-agnostic role as a clinical data contributor across neurological conditions.

Institut Guttmann is moving from condition-specific experimental therapy trials toward multi-disease data science collaborations, positioning themselves as a clinical data hub for AI-driven neurorehabilitation research.

How they like to work

Institut Guttmann has participated exclusively as a consortium partner — never as coordinator — across both H2020 projects, indicating they prefer to contribute specialist clinical capacity rather than lead project management. With 26 unique partners across 10 countries from only 2 projects, their consortia are large and internationally distributed, suggesting they join well-established multi-partner research networks. This profile is consistent with a clinical institution that adds value through patient access and domain expertise, not through research infrastructure or administrative leadership.

Despite only two projects, Institut Guttmann has built connections with 26 partners across 10 countries — an unusually broad network for a small project portfolio, reflecting participation in large pan-European RIA consortia. Their geographic reach is solidly European, with no evidence of partnerships outside EU/associated countries.

What sets them apart

Institut Guttmann is one of the few neurorehabilitation foundations in Southern Europe with a track record in both experimental SCI therapy trials and big-data stroke modeling — a rare combination of clinical depth across two distinct neurological conditions. As a foundation-run specialist center rather than a university hospital, they offer direct and focused patient cohort access without the bureaucratic overhead typical of large academic medical centers. For consortium builders in neurological health research, they fill the critical role of clinical validation partner with real-world patient data.

Highlights from their portfolio

• PRECISE4Q
  The largest-funded of their two projects (€377,190), it tackled personalised stroke prognosis using machine learning and hybrid mechanistic models — demonstrating Institut Guttmann's capacity to contribute clinical data to complex multi-modal AI research.
• NISCI
  A long-running trial (2016–2023) on Nogo-A antibody treatment for acute spinal cord injury — one of the most specific and clinically ambitious neuroregeneration trials in H2020, in which Institut Guttmann contributed specialist SCI patient expertise.